EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Navire Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio and Navire Pharma Doses First Patient in Phase 1 Trial of BBP-398 for RAS and Receptor Tyrosine Kinase Mutation Driven Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$905.0 million","upfrontCash":"$90.0 million","newsHeadline":"BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1\/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen\u2019s LUMAKRAS\u00ae (sotorasib)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridgebio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for Shp2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb\u2019s Opdivo\u00ae (nivolumab)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"LianBio","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for BBP 398

    Menu

    BBP 398

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              LianBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mut...

              Details:

              BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.

              Lead Product(s): BBP-398,Osimertinib Mesylate

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LianBio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with E...

              Details:

              The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung cancer with EGFR mutations.

              Lead Product(s): BBP-398,Osimertinib Mesylate

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BridgeBio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bridgebio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for Shp2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s Opdivo® (nivolumab)

              Details:

              BBP-398 is an investigational SHP2 inhibitor, that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. It is being investigated with opvido for advanced solid tumors.

              Lead Product(s): BBP-398,Nivolumab

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BridgeBio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen’s LUM...

              Details:

              BBP-398 is a SHP2 inhibitor and as a monotherapy or in combination with other targeted therapies, could potentially be a promising therapy for patients with the KRAS G12C mutation.

              Lead Product(s): BBP-398,Sotorasib

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BridgeBio Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

              Details:

              Based on the terms of the agreement, BridgeBio will continue to lead its BBP-398, ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities.

              Lead Product(s): BBP-398

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: $905.0 million Upfront Cash: $90.0 million

              Deal Type: Licensing Agreement May 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bristol Myers Squibb

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398

              Details:

              BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division. First clinical combination study set to evaluate safety and preliminary efficacy in non-small cell lung cancer with KRAS mutations.

              Lead Product(s): BBP-398,Nivolumab

              Therapeutic Area: Oncology Product Name: BBP-398

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: BridgeBio Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BridgeBio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BridgeBio and Navire Pharma Doses First Patient in Phase 1 Trial of BBP-398 for RAS and Receptor Tyrosine Kinase Mutation Driven Tumors

              Details:

              The two-part Phase 1 study will examine the safety and preliminary anti-tumor activity. Part 1 will establish the recommended Phase 2 dose of BBP-398. Part 2 will examine preliminary anti-tumor activity in four cohorts of patients with certain molecular alterations.

              Lead Product(s): BBP-398

              Therapeutic Area: Oncology Product Name: IACS-15509

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Navire Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY